NASDAQ · ONC
Healthcare · Medical - Pharmaceuticals
$370.33
Down-$7.05 (-1.90%)
Updated Nov 2, 2026, 6:47 PM
SID Score
6.0/10
Composite research score
Smart Money
56/100
Neutral
Price performance · ONC
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ONC closed at $370.33 after 20 trading sessions, up 2.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $369.77 | $376.447 | $368.49 | $370.33 | 292.82K |
| Oct 29, 2026 | $373.40 | $376.50 | $368.64 | $371.56 | 268.14K |
| Oct 28, 2026 | $366.64 | $375.81 | $362.505 | $373.36 | 276.52K |
| Oct 27, 2026 | $358.94 | $366.5891 | $353.893 | $366.055 | 518.31K |
| Oct 26, 2026 | $374.14 | $377.16 | $369.705 | $370.87 | 354.61K |
| Oct 23, 2026 | $384.40 | $384.40 | $372.65 | $377.63 | 315.8K |
| Oct 22, 2026 | $378.06 | $384.81 | $375.52 | $382.27 | 359.35K |
| Oct 21, 2026 | $383.51 | $388.66 | $382.6151 | $386.46 | 571.86K |
| Oct 20, 2026 | $374.43 | $384.79 | $373.275 | $384.50 | 408.22K |
| Oct 19, 2026 | $371.53 | $376.34 | $368.51 | $370.17 | 289.75K |
| Oct 16, 2026 | $372.57 | $375.90 | $367.3045 | $369.06 | 431.21K |
| Oct 15, 2026 | $356.61 | $375.64 | $355.24 | $374.08 | 744.87K |
| Oct 14, 2026 | $346.05 | $355.76 | $344.94 | $351.48 | 361.61K |
| Oct 13, 2026 | $354.33 | $354.67 | $348.73 | $349.08 | 287.43K |
| Oct 12, 2026 | $352.55 | $354.15 | $346.61 | $350.40 | 259.3K |
| Oct 9, 2026 | $348.00 | $357.14 | $347.72 | $354.47 | 318.33K |
| Oct 8, 2026 | $351.94 | $355.01 | $340.445 | $350.13 | 418.69K |
| Oct 7, 2026 | $360.01 | $367.57 | $359.4075 | $364.02 | 148.64K |
| Oct 6, 2026 | $365.13 | $368.40 | $359.10 | $362.78 | 319.92K |
| Oct 5, 2026 | $362.48 | $362.83 | $356.82 | $361.65 | 392.12K |
The latest Smart Investors Daily articles mentioning ONC.
Company
Market Activity
Research & News
ONC research
Company profile and research snapshot.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Oct 30, 2026
BeOne Medicines (NASDAQ:ONC) has outperformed the market over the past 10 years by 14.31% on an annualized basis producing an average annual return of 28.04%. Currently, BeOne Medicines has a market capitalization of
SeekingAlpha · Oct 29, 2026
Eli Lilly and Company remains a Buy, as its Q3 results show strong revenue growth and rising Mounjaro and Zepbound sales. Click for a detailed LLY update.
Yahoo · Oct 24, 2026
Americans now have a record share of their financial assets in equities, which raises the stakes for choosing where every new dollar goes. With so much capital already tied to markets, investors are paying closer attention to sectors that can offer essential services through different economic moods. Healthcare fits that bill. This article breaks down three leading healthcare stocks from a curated screener that focuses on financial strength and staying power. The stocks highlighted below are...
Yahoo · Oct 24, 2026
BeOne Medicines (ONC) is back in focus after fresh data at ESMO 2026. The update centered on TEVIMBRA plus ZIIHERA and chemotherapy in HER2-positive gastroesophageal cancer, where longer-term survival figures attracted renewed investor attention. BeOne Medicines has ridden a clear upswing, with a 90 day share price return of 15.87% and a year to date share price gain of 21.42%. The recent ESMO updates and upcoming third quarter results webinar now sit against a three year total shareholder...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ONC.
